This site uses cookies click here  to accept their use   Find out more

Latest News

AllCells is to build a new hematologic tissue collection site in Boston as it looks to expand its offering to life science firms. The clinic, which should be up and running by November, is aimed to “enhance service to life science researchers located throughout US east coast, Europe, and rest of world,”...more
i-Pharm's German team were on the move just before Christmas, moving into a shiny new office at Landsberger Strasse in Munich. A great platform to begin 2017 leaving plenty of room for further expansion of the team in the DACH region....more
i-Pharm is pleased to announce the impending opening of our new North American office in Boston, Massachusetts. This will be a base to service our expanding client base in North America. Further details to follow shortly!...more
i-Pharm is currently recruiting for both trainee and experienced recruitment consultants in our London, Munich & Sydney offices. The next few years promise to be some of the most exciting in our history, with further expansion and new office openings in the pipeline, all of which will create some fantastic opportunities for...more
Quintiles will merge with healthcare information company IMS Health Holdings Inc in a deal worth about $9 billion. The combined company which will have a market value of nearly $18 billion, will offer drug and medical device makers services ranging from helping run clinical trials to tracking sales once a product has...more
On 4th January 2016, i-Pharm will be opening a new office in sunny Sydney! With teams now based in both Sydney and Singapore, we anticipate significant growth across the Asia-Pac region in 2016 and beyond....more
i-Pharm's UK team are on the move! On the 25th September 2015, we will be moving to our purpose-built new home on the banks of the River Thames at Fulham Green, London. The new premises have been secured on a long-term lease. The extra space and upgraded facilities will provide the...more
The European Medicines Agency has published a guide to support implementation of a new international standard for the safety monitoring of medicines due to go live in July 2016.   The new standard - called ISO ICSR - is designed to improve reporting of suspected side effects in Individual Case Safety Reports (ICSRs),...more
The list of drugs to be cut from the Cancer Drugs Fund has yet to be confirmed but drugmakers and doctors have already gone public with their criticisms. It has been reported that six breast cancer drugs are among the treatments to be banned and Eisai has come out most vociferously in...more
Europe’s innovative and generics drugmakers have come together to urge the continent’s lawmakers to adopt an integrated life sciences strategy. Ahead of the adoption of the European Commission’s 2015 work programme, the European Federation of Pharmaceutical Industries and Associations and the European Generic medicines Association have reminded new president Jean-Claude Juncker about...more
Merck & Co has snapped up antibiotics developer Cubist Pharmaceuticals in a deal valued at a total at $9.5 billion. Rumours of a tie-up between the firms  had been gathering force over the weekend- details have now been confirmed. Merck (also know as MSD outside the US and Canada) will aquire Cubist and...more
Shire has claimed the title of pharmaceutical company of the year at the prestigious Pharma Times Marjeter and Communication Team awards, the results of which were annonced in London on November 27th.   Shire was also sucessful in other categories scooping the Cross-Functional Team of the Year (the 'Emerald' team), while Renate Specht...more
Biopharmaceutical company Bristol-Myers Squibb is to build a brand new biologics manufacturing facilitiy in Cruiserath, Co Dublin. An estimated 1,000 construction jobs will be involvesm with 350 jobs expected in the facilita when it is completed in 2019.   The new Bristol-Myers Squibb facility is expected to cost in the region of €700m...more
The European Commission and the European pharmaceutical industry have linked up to launch a 280 million euro call for proposals under the Innovative Medicines Initiative to boost Ebola research.   The funding will cover ''urgent actions addressing the current epidemic and put in place a long-term strategy to manage any future outbreaks''. Some...more
Search giant Google is developing a pill that aims to detect life-threatening illnesses such as cancer and heart disease in the earliest stages. Still in very experimental phase a research unit Google X, the idea behind the pill is that it releases a bunch of nano particles peppered with antibodies or other...more
Roche has unveiled plans to spend 3 billion Swiss francs on upgrading and constructing new labs at its corporate and research home in Basel.   At the heart of the plany is a new research centre ''designed in consultantion with the R&D organisation to ensure that scientists' needs are fully met''. Timetables to...more
Another one bites the dust in the Big Pharma tax inversion craze. Weeks after the U.S Treasury Department laid out new tay rules to limit the stream of corporate inversions, AbbVie ($ABBV) called it quits on its proposed $55 billion takeover of Dublin-based Shire ($SHPG).   The Illinois-based company said Wednesday that it...more
The US Food and Drug Administration has authorised Chimerix' brincidofovir as an emergency treatment for Ebola and it has been taken by the first person diagnosed with the virus in the USA.   The company said that Emergency Investigational New Drug Applications (EIND) were granted by the agency for brincidofovir after requests were...more
Regulators in the USA have fast-tracked a new treatment developed by AstraZeneca's MedImmune unit to prevent pneumonia. Specifically, the US Food and Drug Administration has granted fast-track designation to the investigational monoclonal antibody MEDI3902 for the prevention of nosocomial pneumonia caused by Pseudomonas aeruginosa. The latter is a highly drug-resistant bacterial pathogen...more
An experimental cancer jab being develped by US group Northwest Biotherapeutics is the first medicine to be approved for early use under the UK's new fast-track access programme.   The cell therapy DCVax-L has received the first ever 'Promising Innovative Medicine' (PIM) designation, marking the first step in the new Early Access to...more
Now it's U.K. drug regulators who are devising plans to eavesdrop on social media. But unlike the FDA, which plans to monitor the world of online sharing to see whether its communications are hitting their targets, the Medicines and Healthcare Products Regulatory Agency plans to search for drug safety info.   The ''WEB-RADR''...more
Oral multiple sclerosis is cleared for NHS use in England and Wales.   Multiple sclerosis (MS) patients in England and Wales are set to have access to another oral treatment after Biogen Idec's Tecfidera was recommended by the region's health watchdog. In final guidance the National Institute for Health and Care Excellence (NICE) said...more
GlaxoSmithKline's ($GSK) vaccine candidate for the deadly Ebola virus is ready to roll in human trials. On Thursday, the drugmaker announced it would begin enrolling healthy patients as early as mid-September to test the investigational jab in clinical safety trials. A £2.8 million ($4.64 million) grant from several U.K organisations -including the...more
The UK government and the Wellcome Trust have launched a £6.5 million initiative for emergency Ebola research to tackle the epidemic in West Africa. Proposals will be ‘’reviewed immediately with a view to enabling research to start as soon as possible’’, says the UK’s Department for International Development. Its secretary, Justine Greening...more
The main customer that bought the assets of a Northumberland drug manufacturer said it has no plans to make redundancies.   Health firm Shire has confirmed it has no plans to cut jobs after acquiring the assets of a Northumberland drug manufacturer. The journal exclusively revealed how the assets of SCM Pharma were bought...more
Baxter has officially opened its $370m manufacturing facility for haemophilia A drug Advate in Singapore, shortly after getting EU approval for the plant. EU approval of the Singapore plant allows it to process and supply Advate to the EU, Iceland and Norway, and as additional regulatory approvals come in Baxter will use...more
Drug giant hopes layout will encourage collaboration. The days of secretive drug research will soon be a distant memory for the scientists at one of Britain’s biggest pharma companies.   AstraZeneca has revealed plans to build a network of glass-walled laboratories as part of its new £330m global headquarters in Cambridge. The drug giant on...more
Detailed analysis of Sanofi’s dengue vaccine, the first to show efficacy against the fever, has excited observers even if its benefits are more moderate than had been hoped.   The French giant’s Sanofi Pasteur division announced the publication in The Lancet of its first landmark Phase III dengue vaccine efficacy study conducted in...more
A raft of real world data for Eisai’s Fycompa has been presented at this week’s European Congress on Epileptology in Stockholm. Data on ten Eisai-supported observational studies on clinical experience with adjunctive Fycompa (perampanel) in over 350 refractory patients across sites in the UK and Austria. The results, say Eisai, show perampanel to...more
Abbott (NYSE: ABT) has announced a definitive agreement to acquire Veropharm, a leading Russian pharmaceutical manufacturer. Under the terms of the agreement, Abbott will acquire Limited Liability Company Garden Hills, the holding company that currently owns a controlling interest in Veropharm, for between 13.6 billion rubles  and 17 billion rubles (or...more
Many companies in Europe are embracing in concept of the Unified Patent Court but drugmakers, while positive, are not rushing in opt-in patents on their big products just yet.   That is one of the key points mkade in research published by international legal practice Allen & Overy which demonstrates ''surprising support'' for...more
A month after launching its bid to acquire AstraZeneca, Pfizer has pulled the plug on its £69.4 billion offer for the Anglo-Swedish drug maker, at least for the time being. A few hours before the deadline was reached for a deal to be sealed under UK takeover laws, Pfizer confirmed that following...more
Novartis has announced positive data from a late-stage trial pitting its COPD inhaler Ultibro Breezhaler (indacaterol/glycopyrronium) against combination therapy with tiotropium and formoterol.   The Swiss drug giant said the study meet its primary endpoint of showing non-inferiority of Ultibro Breezhaler compared to tiotropium 18mcg/formoterol 12mcg in improving health-related quality of life outcomes...more
Bayer is paying $14.2 billion for Merck & Co's consumer care business,  pushing the German group to the the global number two position in over-the-counter products. The purchase, which was widely expected after Reckitt Benckiser pulled out of the running for the unit, gives Bayer a portfolio of well-established category-leading products, such...more
Drug giants Novartis and GlaxoSmithKline have sealed a multi-billion-dollar deal which will see the companies exchange assets and form a new consumer healthcare joint venture (JV).   Under the move, GSK is selling its portfolio of cancer drugs to Novartis for up to $16 billion ($14.5 billion upfront, news.5 billion in milestones), and...more
Covance is augmenting its global capabilities for outsourced biologics development with new investment in facilities and additions to its biologics team.   In its home market, the US-based drug-development services company is filling out its large-molecule bioanalytical space co-located with Covance’s central-laboratory facility in Indianapolis, Indiana.    The expanded facilities, which are scheduled to open...more
The global orphan drugs market presents many opportunities for new drug development, and advances in drug discovery capabilities, couples with regulatory and financial incentives, are helping to generate ''rich, competitive pipelines of breakthrough treatments with true disease-modifying properties,'' according to new analysis.   While there are currently only 172 approved orphan therapies, the...more
Experts across academia, industry and government propose a new method for health care providers to get the right treatments to the right patients at the right time. This new approach, A Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials, published in Nature Clinical Pharmacology & Therapeutics, recommends a seamless transition from controlled...more
Sanofi and UCB have entered into a scientific and strategic collaboration for the discovery and development of innovative anti-inflammatory small molecules, which have the potential to treat a wide range of immune-mediated diseases in areas such as gastroenterology and arthritis.   "Immune-mediated diseases affect individuals, families, and communities and impact the economies of...more
Mid-stage data on Roche's lebrikizumab shows that the drug significantly reduced attacks in patients with severe uncontrolled asthma, providing a personalised approach to the condition. The Swiss major has presented Phase IIb data at the American Academy of Allergy, Asthma and Immunology meeting in San Diego which show that asthma attacks were...more
Novartis has become the lastest pharmaceutical company to introduce a controlled access route to patient level data from its clinical trials. Researchers can now request access to patient-levek data on the companyÄs newly approved innovative medicines in the United States and European Union through the ideaPoint portal.   In Januyry, it emerged that Boehringer...more
FDA panel  could give Bayer painkiller an edge over rivals Pfizer,  J&J. What if every drug in a class posed a risk to the heart-all expect one? That's the question we could soon be asking about nosteroidal anti-flammatories, or NSAIDs, among the commonly used drugs in the world.      ...more
US based biopharmaceutical services provider PAREXEL International has rebranded its technology subsidiary, Perceptive Informatics, to PAREXEL Informatics as part of an ongoing effort to create a more integrated package of services.   The Perceptive brand will be retained for specific PAREXEL Informatics offerings, including the Perceptive MyTrials eClinical platform, the Perceptive Partner Program...more
Global CRO Covance boosted its revenue by about 11% last quater, capping off a banner year in which the company outstripped it financial targets.   Covance cleared $623.1 million in revenue in the fourth quater of 2012, above the prior years's $562.2 million, and increased its net income by 35% to  $45.8 million. For...more
Ablynx has signed an oncology pact with Merck & Co which could be worth up to 1.7 billion euros to the Belbium-based biotech. The companies, which signed a neuroscience deal in 2012, are linking up again to direct Ablynx-discovered nanobodies (a novel class of therapeutic proteins) towards "immune checkpoint modulators," proteins which...more
Johnson & Johnson has launched a new unit to centralise its activities in the developing world, covering the spectrum from clinical research to improving access to its treatments. Janssen Global Public Health (Janssen GPH) has been formed to "align the company's groundbreaking science and innovative access models under a single entity". It...more
Sanofi has linked up with the German applied research group Fraunhofer-Gesellschaft to discover antibiotics derived from natural products. The French drugmaker and Fraunhofer have announced the creation of "a natural product centre of excellence" to accelerate the discovery and development of new therapies to treat infectious diseases". The partners, noting that penicillin...more
The US Food and Drug Administration has finally approved AstraZeneca's diabetes drug Farxiga but is insisting on six post-marketing studies, including a cardiovascular outcomes trial. The approval was expected given that the agency's Endocrinologic and Metabolic Drugs Advisory Committee voted 13-1 last month that the benefits of Farxiga (dapagliflozin), already marketed in...more
For a long time, pharma companies have looked to large disease populations as the biggest potential revenue streams. But those days are long gone. That perception has shifted, especially with the prescription drug market stagnating in the U.S. and Europe. Orphan drugs--pharmaceutical treatments for rare diseases or disorders--have proven themselves as viable...more
Europe's regulators had approved a new formulation of Roche's breast cancer drug Herceptin which will slash the time needed to administer the blockbuster.   The European Commission has given the green light to a new injectable formulation of Herceptin (trastuzumab) for HER2-positive breast cancer. The subcutaneous formulation is administered in two to five...more
GlaxoSmithKline's ($GSK) Rotarix and Merck's ($MRK) RotaTeq, vaccines designed to fight rotavirus, did their jobs, a Journal or the American Medical Association (JAMA) study found. The number of the rotavirus-related hospitalizations in kids under 5 fell by 80% after the shots went into routine use, and  the hospitalizations in kids 5-14...more
Quintiles, the US-based provider of biopharmaceutical development and commercial outsourcing services, has agreed to acquire Novella Clinical, a full-service clinical research organisation (CRO) focused mainly on emerging oncology, medical devices and diagnostics customers.   No financial terms were disclosed for the deal, which is subject to the usual closing conditions and is expected...more
Novartis is the first company to earn global CEO Cancer Gold Standard accreditation by the non-profit organization CEO Roundtable on Cancer, a group of cancer fighting CEOs from a variety of industries, including healthcare. The designation recognizes the company's efforts to provide support to Novartis associates in the prevention, diagnosis and...more
  An FDA panel of outside experts has contributed a round of thumbs-up for Bayer's new drug for pulmonary arterial hypertension, to be sold as Adempas, sending the pharma giant on what appears to be another victory lap in the lead-up to a likely approval.   The group voted unanumously in favor of riociguat,...more
The Raleigh-based contract research organization PRA International is merging with ReSearch Pharmaceutical Services, of Pennsylvania, according to PRA’s private-equity owner. Kohlberg Kravis Roberts & Co (NYSE: KKR), the New York investment firm that acquired PRA in June, said Wednesday that it is now acquiring RPS from Warburg Pincus and will merge it...more
Uptake of new cancer treatments helped Roche to a 5 per cent increase in sales in the first half of 2013, while profits topped market expectations. Group sales for the six months were 23.3bn Swiss francs ($24.77bn) while operating profit rose 10 per cent to 9.48bn Swiss francs. Earnings per share (EPS)...more
Novartis CEO Joe Jimenez has outlined the firm's determination to be the major force in biosimilars. Speaking as the Swiss major posted its financials for the second quarter (see link), Mr Jimenez (pictured) highlighted the advancement of its biosimilars pipeline. He noted that Novartis' Sandoz unit is running seven Phase III studies...more
  Want a new job in pharma? The world's biggest drugmakers are hiring--even in the U.S. and Europe. The numbers aren't enormous, but as Genetic Engineering & Biotechnology News numbers show, the three most active recruiters have more than 5,000 positions to fill among them. Over the past few years, we've grown...more
The Novartis Prizes for Immunology are awarded to three scientists for their groundbreaking research into the biology of immune system T cells that advanced the prevention and treatment of a variety of diseases. The Prize ceremony will take place at the 15th International Congress of Immunology in Milan, Italy on August 23,...more
   Fresh from making a deal with activist investor Carl Icahn, Forest Laboratories ($FRX) has been thrust into the mix of potential bidders for the Ireland-based biotech company Elan ($ELN). Unnamed sources told Reuters that the U.S. drugmaker was among the parties interested in bidding on Elan, and Forest apparently fits...more
The US Food and Drug Association has approved Sanofi's supplemental biologics license application for Fluzone Quadrivalent, which the company  says is the first-and-only four-strain influenza vaccine for patients as young as six months of age.   The French drugmaker's Sanofi Pasteur unit notes that like its existing Fluzone vaccine, which is administered to more...more
Bill Gates has added his high-profile name and dollars to the open-science movement, joining other investors in a $35 million financing round for the 5-year-old social network for scientists called ResearchGate.  It's one of the latest investments from the Microsoft ($MSFT) chairman and world's richest man that focuses on supporting translation of...more
Novartis is joining the global multiple sclerosis (MS) community in celebration of World MS Day by launching a new campaign and participating in initiatives that encourage information and experience exchange around MS.  Novartis is committed to supporting the MS community through these initiatives, in addition to delivering and researching innovative treatments to...more
Two Swiss billionaires--Ernesto Bertarelli and Hansjörg Wyss--have joined forces to buy out the former Merck Serono facility in Geneva, with ambitious plans to create a major collaboration on discovery work and translational research while offering a home for a new generation of biotech companies in the region....more
Fresh from returning to public ownership with a US$947 million offering, Quintiles has made a significant addition to its roster of strategic alliances in the form of a five-year clinical development agreement with Merck Serono. In fact, the agreement involves a level of co-operation beyond that usually seen in what is now...more
The R&D numbers for the top 10 biotechs may only amount to a fraction of what you'll find in Big Pharma. But unlike the giants, which are trying to keep a lid on multibillion-dollar budgets, you'll find a much faster crowd when you turn your gaze to the biotechs.  All 10 reported...more
H.Lundbeck has introduced the first approved medication reducing alcohol consumption in alcohol dependent patients in Norway, Finland, Poland and the Baltic markets.   Additional launches in other European countries are expected to follow later in 2013 and 2014. Lundbeck international markets and Europe senior vice president Ole Chrintz said, "This is an area with...more
Parexel delivered another strong quarter of growth in revenue and operating profits, ahead of analysts’ estimates, for the three months ended 31 March 2013.   The company also bolstered its capabilities in the market-access space by acquiring Heron Group, a life sciences consultancy that provides evidence-based commercialisation services to biopharmaceutical companies throughout the...more
i-Pharm's new German office opened for business at Theresienhoehe 28, Munich, on Tuesday 2nd April 2013. This is an exciting development for the company and demonstrates our ongoing commitment to servicing the needs of our clients and candidates in the DACH region....more
Johnson & Johnson has posted an 8.5% increase in sales for the first quarter, helped by a strong showing at its pharmaceuticals division. Group net income came in at $3.50 billion, down 10.6% compared to the like, year-earlier period which was affected by litigation and integration charges of $600 million. Turnover reached $17.51 billion. Worldwide pharmaceutical sales...more
Valeant Pharmaceuticals and Actavis  are getting downright buddy-buddy. Less than a week after partnering up on three skin products, the two companies have wrapped up a patent fight over two others. The settlement sets launch dates for both copycat versions, and gives Valeant a share in the proceeds. The new patent deal involves...more
The FDA has endorsed Pfizer's ($PFE) high hopes for the breast cancer drug palbociclib (or PD-0332991), handing out its coveted "breakthrough" drug status after posting some impressive interim results from a mid-stage study tracking progression-free survival among breast cancer patients. Palbociclib, which Pfizer CEO Ian Read recently singled out as one of the pharma...more
i-Pharm's DACH region team will be relocating to a brand new office in Munich, Germany, opening on 2nd April 2013. i-Pharm has been operational in the German and Swiss markets since 2008 and the opening of the new DACH region HQ is a further commitment to expanding the business in the...more
US regulators have approved, for the first time, a patch to treat migraine, claimed by its makers to be a "game-changing" new treatment option for sufferers - particularly for those also affected by related nausea. The US Food and Drug Administration has issued a green light for NuPathe's Zecuity to relieve migraine-related...more
Takeda is paying $60 million upfront to acquire the USA's LigoCyte Pharmaceuticals and expand its vaccines business.   The Japan-based major will pay more depending on the progress of certain projects being developed by LigoCyte, a privately-held company headquartered in Bozeman, Montana. Its lead product, a vaccine to prevent norovirus gastroenteritis, is in...more
Anyone who follows pharma knows that FDA has called manufacturers on the carpet quite often over the past few years. One by one, some of the biggest names in the industry have had to ratchet back or suspend production to fix some scary-sounding manufacturing violations. The New York Times catalogs some of...more
Penny-pinching governments have put pharma's head in a vise, Bayer CEO Marijn Dekkers says. Joining a chorus of pharma executives, Dekkers warned that continuing to squeeze drug prices will crush innovation and drain the lifeblood from the R&D-based business model. "The profits that we make on the current drugs really source and...more
Almost 30 years after discovery of a link between alcohol consumption and certain forms of cancer, scientists are reporting the first evidence from research on people explaining how the popular beverage may be carcinogenic. The results, which have special implications for hundreds of millions of people of Asian descent, were reported...more
The pharmaceutical company Boehringer Ingelheim has grown again in the current financial year. In the first half of 2012, currency-adjusted sales increased by 6.8% compared with the previous year to €7.1 billion. The increased sales were driven by the established respiratory tract medication SPIRIVA® and COMBIVENT®, both of which experienced double-digit...more
As part of i-Pharm's continued growth in 2012, July saw the arrival of 2 new consultants, Will Hitchcock and Aoife Cronin. Will and Aoife will be bolstering our Pharmaceutical Manufacturing and Health Economics teams respectively - both sectors that have grown exponentially for i-Pharm in the last 12 months....more
i-Pharm has continued to grow it's team covering the Pharmaceutical market in the DACH region (Germany, Austria, Switzerland). We now have a team of 5 native German speakers covering the region and plan to further grow this team in 2012! New office in Munich scheduled to open in H1 2013!...more
On the evening of the 16th February, the great and the good of the UK Pharmaceutical industry gathered in the Riverbank Plaza Hotel in London for the annual Pharmatimes Clinical Research awards. We are delighted to announce that our very own Stephen McAnaney was nominated in the Clinical Recruiter category. Unique to...more
Keyword Search
Job Type